Literature DB >> 33675908

TERT promoter mutations and melanoma survival: A comprehensive literature review and meta-analysis.

Sara Gandini1, Ines Zanna2, Simone De Angelis1, Domenico Palli2, Sara Raimondi1, Simone Ribero3, Giovanna Masala2, Mariano Suppa4, Federica Bellerba1, Federica Corso1, Luigi Nezi1, Eduardo Nagore5, Saverio Caini6.   

Abstract

We conducted a systematic review and meta-analysis of the association between somatic mutations of the TERT gene promoter and melanoma survival. Data from nineteen independent studies (>2,500 melanoma overall) were pooled using random effects meta-analysis models. TERT-mutated melanoma patients had a significantly worse overall survival (OS) (summary hazard ratio 1.43, 95 % confidence intervals (CI) 1.05-1.95) compared to wild-type ones. The association became stronger when combining risk estimates for overall and melanoma-specific survival (MSS) (1.52, 95 % CI 1.14-2.02), and when restricting the analysis to studies mostly based on invasive non-acral cutaneous melanomas (1.77, 95 % CI 1.00-3.15). Limited, yet suggestive evidence of a detrimental effect of TERT promoter mutations on melanoma prognosis emerged also for other survival measures (e.g. disease-free and distant metastasis-free survival). We found suggestive evidence of a detrimental effect of TERT mutations on melanoma patients' survival.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Melanoma; Meta-analysis; Review; Survival; Telomerase reverse transcriptase gene promoter

Mesh:

Substances:

Year:  2021        PMID: 33675908     DOI: 10.1016/j.critrevonc.2021.103288

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  1 in total

1.  Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.

Authors:  Russell J Diefenbach; Jenny H Lee; Ashleigh Stewart; Alexander M Menzies; Matteo S Carlino; Robyn P M Saw; Jonathan R Stretch; Georgina V Long; Richard A Scolyer; Helen Rizos
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.